In race to stop Covid-19, Indian drugmakers to conduct clinical trials

Glenmark, Zydus Cadila to start trials in May

If the trials go along expected lines, we will soon have an antiviral drug (Favipiravir) for Covid-19 patients in the market.

Glenmark Pharmaceuticals is all set to start clinical trials on mild to moderate coronavirus-positive patients in May.
 

Meanwhile, several other Indian firms are stepping up efforts to start clinical trials on other drug candidates — such as biologic drug Interferon alfa-2b and antiviral drug Remdesivir.
 

Cadila Healthcare (Zydus Cadila) will start clinical trials on Interferon alfa-2b, a drug that it already makes commercially for Hepatitis C, for the novel coronavirus.